Furosemide

Generic Name: Furosemide

Brand Names: Furoscix, Lasix

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₁ClN_₂O_₅S

CAS Number: 54-31-9

Unique Ingredient Identifier: 7LXU5N7ZO5

Background: Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...

Indication: Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...

Associated Conditions: Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion

Associated Therapies: -

Clinical Trials

Lasix for the Prevention of De Novo Postpartum Hypertension

Phase 3

Completed

Conditions: Postpartum Pregnancy-Induced Hypertension
Postpartum Preeclampsia
Hypertension
Hypertension, Pregnancy-Induced

Interventions: Other: Placebo
Drug: Furosemide

First Posted Date: 2021-02-12

Last Posted Date: 2024-12-13

Lead Sponsor: Columbia University

Target Recruit Count: 82

Registration Number: NCT04752475

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

OUTpatient Intravenous LASix Trial in Reducing Hospitalization for Acute Decompensated Heart Failure

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: IV Solution
Drug: Furosemide

First Posted Date: 2020-12-31

Last Posted Date: 2020-12-31

Lead Sponsor: New York Presbyterian Brooklyn Methodist Hospital

Target Recruit Count: 100

Registration Number: NCT04691687

Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

Phase 3

Completed

Conditions: Heart Failure，Congestive

Interventions: Drug: Furosemide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: University of Palermo

Target Recruit Count: 136

Registration Number: NCT04628325

Locations: 🇮🇹
AOUP Paolo Giaccone, Palermo, Italy
🇮🇹
Internal Medicine Ward of Palermo University Hospital, Palermo, Italy

Furosemide vs. Placebo for Severe Antepartum Hypertension

Phase 3

Completed

Conditions: Pregnancy Complications
Hypertension, Pregnancy-Induced
Pre-Eclampsia
Hypertension in Pregnancy

Interventions: Other: Placebo
Drug: Furosemide

First Posted Date: 2020-11-04

Last Posted Date: 2024-04-18

Lead Sponsor: Melanie Maykin, MD

Target Recruit Count: 65

Registration Number: NCT04615624

Locations: 🇺🇸
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States

Influence of Diuresis Timing (F+0 Vs F-15) on 99m Tc DTPA Renography for the Diagnosis of Suspected Obstructive Uropathy

Conditions: Renal Scan in Suspected Obstructive Uropathy in Adult Hydronephrotic Patient

First Posted Date: 2020-09-25

Last Posted Date: 2020-09-25

Lead Sponsor: Assiut University

Target Recruit Count: 50

Registration Number: NCT04564469

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MT-1186
Drug: Rosuvastatin
Drug: Furosemide
Drug: Sildenafil

First Posted Date: 2020-07-22

Last Posted Date: 2024-08-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 84

Registration Number: NCT04481789

Locations: 🇯🇵
Investigational site, Tokyo, Japan

Postpartum Management of Gestational Hypertensive Disorders Using Furosemide

Phase 4

Terminated

Conditions: Hypertension, Pregnancy-Induced

Interventions: Drug: furosemide
Drug: labetalol

First Posted Date: 2020-04-13

Last Posted Date: 2023-10-23

Lead Sponsor: Wright State University

Target Recruit Count: 13

Registration Number: NCT04343235

Locations: 🇺🇸
Miami Valley Hospital, Dayton, Ohio, United States

Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

Phase 4

Recruiting

Conditions: Fluid Overload

Interventions: Drug: Isotonic saline
Drug: Furosemide

First Posted Date: 2019-11-27

Last Posted Date: 2024-11-25

Lead Sponsor: Morten H. Bestle

Target Recruit Count: 1000

Registration Number: NCT04180397

Locations: 🇩🇰
Department of Intensive Care, Sygehus Sønderjylland Aabenraa, Aabenraa, Denmark
🇩🇰
Departmen of Intensive Care, Aalborg, Denmark
🇩🇰
Dorte Illum, Aarhus, Denmark

and more 17 locations

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Phase 2

Completed

Conditions: Heart Failure (HF)

Interventions: Other: Placebo BAY 1753011
Drug: BAY 1753011
Other: Placebo Furosemide
Drug: Furosemide

First Posted Date: 2019-04-03

Last Posted Date: 2022-04-18

Lead Sponsor: Bayer

Target Recruit Count: 482

Registration Number: NCT03901729

Locations: 🇦🇹
Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria
🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇦🇹
Universitätsklinikum AKH Wien, Wien, Austria

and more 63 locations

Protocol of Diuretics Use in Congestive Therapy in Heart Failure

Phase 4

Conditions: Heart Failure
Chronic Heart Failure
Acute Heart Failure

Interventions: Drug: Furosemide
Drug: Hydrochlorothiazide

First Posted Date: 2019-03-27

Last Posted Date: 2021-04-15

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 300

Registration Number: NCT03892148

Locations: 🇫🇷
Ch Annecy, Annecy, France
🇫🇷
CH PUY, Le Puy-en-Velay, France
🇫🇷
CHU de GRENOBLE, Grenoble, France

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy